Skip to content

When and How to Administer Oxytocin for Active Management of Third Stage of Labour

When and How to Administer Oxytocin for Active Management of Third Stage of Labour

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01954186
Enrollment
600
Registered
2013-10-01
Start date
2010-01-31
Completion date
2010-12-31
Last updated
2013-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Bleeding

Keywords

Oxytocin, Active Management of Third Stage of Labour

Brief summary

To compare the efficacy of the route and timing of oxytocin administration for Active management of third stage of labour (AMTSL).

Detailed description

Our objective is to determine the most efficient route and timing of oxytocin administration by measuring the duration of third stage of labour, quantitative blood during the first hour after delivery and comparing haemoglobin and haematocrit changes and the need for additional interventions in patients who had either a spontaneous labour or received labour augmentation with oxytocin.

Interventions

DRUGintravenous & intramuscular oxytocin

intravenous or intramuscular 10 iu oxytocin

PROCEDUREafter delivery of the fetus & when anterior shoulder seen

oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered

Sponsors

Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
Lead SponsorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* having a singleton pregnancy above 37th gestational week * normal live vaginal delivery with cephalic presentation * being in active labor

Exclusion criteria

* Fetal demise * multiple pregnancy * known coagulation disorder * presentation anomalies * placental pathology * liver disease * thrombocytopenia * hypertension or being currently on anticoagulants * having a cesarean section, operative delivery or deep vaginal tear * chorioamnionitis * developing HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) or DIC (disseminated intravascular coagulation) before delivery

Design outcomes

Primary

MeasureTime frame
postpartum bleeding in the third stage of labourparticipants will be followed for the duration of hospital stay, an expected average of 48 hours

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026